{
    "id": 26142,
    "fullName": "KDM6A loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "KDM6A loss indicates loss of the KDM6A gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 7403,
        "geneSymbol": "KDM6A",
        "terms": [
            "KDM6A",
            "bA386N14.2",
            "KABUK2",
            "UTX"
        ]
    },
    "variant": "loss",
    "createDate": "03/09/2017",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10232,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK343 inhibited proliferation of KDM6A-null urothelial bladder carcinoma cell lines in culture, and delayed tumor onset, improved survival, and inhibited tumor growth in xenograft models (PMID: 28228601).",
            "molecularProfile": {
                "id": 27321,
                "profileName": "KDM6A loss"
            },
            "therapy": {
                "id": 2701,
                "therapyName": "GSK343",
                "synonyms": null
            },
            "indication": {
                "id": 4006,
                "name": "bladder urothelial carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8173,
                    "pubMedId": 28228601,
                    "title": "Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28228601"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12775,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KDM6A-null urothelial bladder carcinoma cell lines demonstrated sensitivity to GSK126, resulting in decreased proliferation in culture (PMID: 28228601).",
            "molecularProfile": {
                "id": 27321,
                "profileName": "KDM6A loss"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 4006,
                "name": "bladder urothelial carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8173,
                    "pubMedId": 28228601,
                    "title": "Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28228601"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12776,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KDM6A-null urothelial bladder carcinoma cell lines demonstrated sensitivity to Tazemetostat (EPZ-6438), resulting in decreased proliferation in culture (PMID: 28228601).",
            "molecularProfile": {
                "id": 27321,
                "profileName": "KDM6A loss"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 4006,
                "name": "bladder urothelial carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8173,
                    "pubMedId": 28228601,
                    "title": "Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28228601"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12774,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK503 inhibited tumor growth in a cell line xenograft model and in a patient-derived xenograft (PDX) model of KDM6A-null urothelial bladder carcinoma (PMID: 28228601).",
            "molecularProfile": {
                "id": 27321,
                "profileName": "KDM6A loss"
            },
            "therapy": {
                "id": 6646,
                "therapyName": "GSK503",
                "synonyms": null
            },
            "indication": {
                "id": 4006,
                "name": "bladder urothelial carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8173,
                    "pubMedId": 28228601,
                    "title": "Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28228601"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12779,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a multiple myeloma cell line demonstrated sensitivity to treatment with GSK126, resulting in decreased viability in culture and decreased tumor growth in xenograft models (PMID: 29045832).",
            "molecularProfile": {
                "id": 27321,
                "profileName": "KDM6A loss"
            },
            "therapy": {
                "id": 2925,
                "therapyName": "GSK126",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10712,
                    "pubMedId": 29045832,
                    "title": "UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29045832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12778,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a multiple myeloma cell line with KDM6A loss demonstrated sensitivity to treatment with GSK343, resulting in cell-cycle arrest and increased apoptosis in culture (PMID: 29045832).",
            "molecularProfile": {
                "id": 27321,
                "profileName": "KDM6A loss"
            },
            "therapy": {
                "id": 2701,
                "therapyName": "GSK343",
                "synonyms": null
            },
            "indication": {
                "id": 9538,
                "name": "multiple myeloma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10712,
                    "pubMedId": 29045832,
                    "title": "UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29045832"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27321,
            "profileName": "KDM6A loss",
            "profileTreatmentApproaches": [
                {
                    "id": 16731,
                    "name": "EZH2 inhibitor",
                    "profileName": "KDM6A loss"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}